Literature DB >> 25210554

Application of bone scans for prostate cancer staging: Which guideline shows better result?

Ari Chong1, Insang Hwang2, Jung-Min Ha1, Seong Hyeon Yu2, Eu Chang Hwang2, Ho Song Yu2, Sun Ouck Kim2, Seung-Il Jung2, Taek Won Kang2, Dong Deuk Kwon2, Kwangsung Park2.   

Abstract

INTRODUCTION: We evaluated the accuracy of current guidelines by analyzing bone scan results and clinical parameters of patients with prostate cancer to determine the optimal guideline for predicting bone metastasis.
METHODS: We retrospectively analyzed patients who were diagnosed with prostate cancer and who underwent a bone scan. Bone metastasis was confirmed by bone scan results with clinical and radiological follow-up. Serum prostate-specific antigen, Gleason score, percent of positive biopsy core, clinical staging and bone scan results were analyzed. We analyzed diagnostic performance in predicting bone metastasis of the guidelines of the European Association of Urology (EAU), American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN) guidelines as well as Briganti's classification and regression tree (CART). We also compared the percent of positive biopsy core between patients with and without bone metastases.
RESULTS: A total 167 of 806 patients had bone metastases. Receiver operating curve analysis revealed that the AUA and EAU guidelines were better for detecting bone metastases than were Briganti's CART and NCCN. No significant difference was observed between AUA and EAU guidelines. Patients with bone metastases had a higher percent positive core than did patients without metastasis (the cut-off value >55.6).
CONCLUSION: The EAU and AUA guidelines showed better results than did Briganti's CART and NCCN for predicting bone metastasis in the enrolled patients. A bone scan is strongly recommended for patients who have a higher percent positive core and who meet the EAU and AUA guidelines.

Entities:  

Year:  2014        PMID: 25210554      PMCID: PMC4137016          DOI: 10.5489/cuaj.2054

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  19 in total

1.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

2.  Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis.

Authors:  Nobumichi Tanaka; Kiyohide Fujimoto; Takayuki Shinkai; Yasushi Nakai; Masaomi Kuwada; Satoshi Anai; Makito Miyake; Akihide Hirayama; Masatoshi Hasegawa; Yoshihiko Hirao
Journal:  Jpn J Clin Oncol       Date:  2011-08-23       Impact factor: 3.019

3.  The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population.

Authors:  Danil V Makarov; Rani A Desai; James B Yu; Richa Sharma; Nitya Abraham; Peter C Albertsen; David F Penson; Cary P Gross
Journal:  J Urol       Date:  2011-11-16       Impact factor: 7.450

4.  Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.

Authors:  Shigeru Kosuda; Ichiro Yoshimura; Taku Aizawa; Kiyoshi Koizumi; Koichiro Akakura; Junpei Kuyama; Kiyoshi Ichihara; Junji Yonese; Mitsuru Koizumi; Jun Nakashima; Hirofumi Fujii
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

5.  Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs.

Authors:  Aaron D Falchook; Ramzi G Salloum; Laura H Hendrix; Ronald C Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-12-07       Impact factor: 7.038

6.  [Are bone scintigraphy examinations requested in oncologic patients according to established indications?].

Authors:  M Cortés Romera; M P Talavera Rubio; A M García Vicente; S Ruiz Solís; V M Poblete García; B Rodríguez Alfonso; A Palomar Muñoz; A Soriano Castrejón
Journal:  Rev Esp Med Nucl       Date:  2007 Sep-Oct

7.  Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.

Authors:  Miranda H Y Lai; Wing Hang Luk; James C S Chan
Journal:  Urol Oncol       Date:  2009-09-06       Impact factor: 3.498

8.  When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.

Authors:  Alberto Briganti; Niccolò Passoni; Matteo Ferrari; Umberto Capitanio; Nazareno Suardi; Andrea Gallina; Luigi Filippo Da Pozzo; Maria Picchio; Valerio Di Girolamo; Andrea Salonia; Liugi Gianolli; Cristina Messa; Patrizio Rigatti; Francesco Montorsi
Journal:  Eur Urol       Date:  2009-12-18       Impact factor: 20.096

9.  Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

Authors:  Seung Hwan Lee; Mun Su Chung; Kyung Kgi Park; Chan Dong Yom; Dae Hoon Lee; Byung Ha Chung
Journal:  World J Urol       Date:  2011-07-16       Impact factor: 4.226

10.  The utilization of Gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients.

Authors:  Chad W M Ritenour; John T Abbott; Michael Goodman; Naomi Alazraki; Fray F Marshall; Muta M Issa
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more
  1 in total

Review 1.  Imaging of Oligometastatic Disease.

Authors:  Naik Vietti Violi; Rami Hajri; Laura Haefliger; Marie Nicod-Lalonde; Nicolas Villard; Clarisse Dromain
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.